英文名称 |
中文名称 |
CAS号 |
操作 |
3-AP;OCX191;PAN-811;NSC663249;Triapine |
[(3-氨基吡啶-2-基)亚甲基氨基]硫脲 |
143621-35-6 |
详细
|
MC1568 |
MC1568 |
852475-26-4 |
详细
|
PH-797804;PH797804 |
PH-797804 |
586379-66-0 |
详细
|
DBEQ;JRF 12 |
DBEQ |
177355-84-9 |
详细
|
RN486 |
RN 486 |
1242156-23-5 |
详细
|
WHI-P180;Janex 3 |
3-[(6,7-二甲氧基-4-喹唑啉基)氨基]苯酚 |
211555-08-7 |
详细
|
(S)-P7C3-OMe;(R)-P7C3-Ome |
(R)-1-(3,6-二溴-9H-咔唑-9-基)-3-(3-甲氧基苯基氨基)丙烷-2-醇 |
1235481-43-2 |
详细
|
ISRIB |
ISRIB |
548470-11-7 |
详细
|
TH588 |
TH588 HYDROCHLORIDE |
1609960-31-7 |
详细
|
(S)-Metolachor |
异丙甲草胺 |
87392-12-9 |
详细
|
RG108;N-Phthalyl-L-tryptophan |
RG108 |
48208-26-0 |
详细
|
α-Muricholic acid |
α-鼠胆酸 |
2393-58-0 |
详细
|
Tiplaxtinin;PAI-039;Tiplasinin |
替普沙汀 |
393105-53-8 |
详细
|
(R)-3-Hydroxyisobutyric acid |
(R)-2-羟甲基丙酸 |
1910-47-0 |
详细
|
LY294002;LY 294002;SF 1101;NSC 697286 |
LY294002/PI3K抑制剂 |
154447-36-6 |
详细
|
Fedratinib;TG-101348;SAR 302503 |
N-(1,1-二甲基乙基)-3-[[5-甲基-2-[[4-[2-(1-吡咯烷基)乙氧基]苯基]氨基]-4-嘧啶基]氨基]苯磺酰胺 |
936091-26-8 |
详细
|
GSK-923295;GSK923295 |
3-氯-N-{(1S)-2-[(N,N-二甲基甘氨酰)氨基]-1-[(4-{8-[(1S)-1-羟基乙基]咪唑并[1,2-A]吡啶-2-基}苯基)甲基]乙基}-4-[(1-甲基乙基)氧基]苯甲酰胺 |
1088965-37-0 |
详细
|
Cinaciguat;BAY 58-2667 |
CINACIGUAT |
329773-35-5 |
详细
|
ISX-9;Isoxazole 9 (ISX-9);Isoxazole 9;Isx 9 |
ISX 9 |
832115-62-5 |
详细
|
WS3 |
重复 |
1421227-52-2 |
详细
|
RGW 611 |
4-(2-(4-NITRO-1H-IMIDAZOL-1-YL)ETHYL)MORPHOLINE |
6497-78-5 |
详细
|
Atopaxar Hydrobromide |
阿托帕沙溴酸 |
474550-69-1 |
详细
|
PFI-4;PFI4;PFI 4 |
N-(1,3-二甲基-2-氧代-6-(吡咯烷-1-基)-2,3-二氢-1H-苯并[D]咪唑-5-基)-2-甲氧基苯甲酰胺 |
900305-37-5 |
详细
|
Nimorazole;Nimorazol;Naxogin;K-1900;Nitrimidazine |
尼莫拉唑 |
6506-37-2 |
详细
|
HA14-1 |
乙基-2-氨基-6-溴-4-(1-氰基-2-乙氧基-2-甲酰)-4H-苯并呋喃-3-羧酸 |
65673-63-4 |
详细
|
Luminespib;AUY922;NVP-AUY922;VER-52296 |
NVP-AUY922 |
747412-49-3 |
详细
|
WHI-P154;Jak3 inhibitor ii |
2-溴-4-(6,7-二甲氧基喹唑啉-4-基氨基)苯酚 |
211555-04-3 |
详细
|
PF-4708671;PF 4708671;PF4708671 |
PF-4708671 |
1255517-76-0 |
详细
|
OAC2 |
OAC2 |
6019-39-2 |
详细
|
Bikinin;Abrasin |
Bikinin |
188011-69-0 |
详细
|
OAC1;BAS 00287861 |
N-1H-吡咯并[2,3-C]吡啶-5-基苯甲酰胺 |
300586-90-7 |
详细
|
RKI1313;RKI-1313;RKI 1313 |
1-(3-METHOXYBENZYL)-3-(4-(PYRIDIN-4-YL)THIAZOL-2-YL)UREA |
1342276-76-9 |
详细
|
CZC-54252;CZC 54252;CZC54252 |
CZC-54252 |
1191911-27-9 |
详细
|
GSK-5959;GSK 5959 |
化合物GSK 5959 |
901245-65-6 |
详细
|
Varespladib;LY315920 |
伐瑞拉迪 |
172732-68-2 |
详细
|
Fexaramine |
FEXARAMINE |
574013-66-4 |
详细
|
A-803467;A803467;A 803467 |
5-(4-氯苯基)-N-(3,5-二甲氧基苯基)-2-呋喃甲酰胺 |
944261-79-4 |
详细
|
Gedatolisib;PKI-587;PF-05212384 |
N-[4-[[4-(二甲基氨基)-1-哌啶基]羰基]苯基]-N'-[4-[4,6-二(4-吗啉基)-1,3,5-三嗪-2-基]苯基]脲 |
1197160-78-3 |
详细
|
CYM5442 |
CYM5442 |
1094042-01-9 |
详细
|
JNJ-31020028;JNJ 31020028;JNJ31020028 |
JNJ 31020028 |
1094873-14-9 |
详细
|
WAY-262611;WAY262611;WAY 262611 |
MAY-262611 |
1123231-07-1 |
详细
|
S0859 |
NBC抑制剂(S0859) |
1019331-10-2 |
详细
|
Duvelisib;INK1197;IPI-145 |
IPI-145 |
1201438-56-3 |
详细
|
Tubastatin A;Tubastatin A BASE |
TUBASTATIN A |
1252003-15-8 |
详细
|
AG1557;AG-1557;AG 1557 |
AG-1557 |
189290-58-2 |
详细
|
WHI-P258 |
WHI-P258 |
21561-09-1 |
详细
|
Dihydroethidium;Hydroethidine;PD-MY 003 |
二氢乙锭 |
104821-25-2 |
详细
|
LY-364947;LY 364947;LY364947;HTS466284 |
LY 364947 |
396129-53-6 |
详细
|
CHS-828;GMX1778;CHS 828 |
N-[6-(4-氯苯氧基)己基]-N'-氰基-N''-4-吡啶基胍 |
200484-11-3 |
详细
|
Pictilisib;RG7321;GDC-0941 |
GDC-0941 |
957054-30-7 |
详细
|
PF-573228;PF 573228 |
6-[(4-((3-(甲磺酰基)苄基)氨基)-5-三氟甲基嘧啶-2-基)氨基]-3,4-二氢-1H-喹啉-2-酮 |
869288-64-2 |
详细
|
CAY10603;BML-281;HDAC6 Inhibitor |
HDAC6 Inhibitor |
1045792-66-2 |
详细
|
HDAC-IN-7;HBI-8000;CS055;Chidamide |
西达本胺 |
743420-02-2 |
详细
|
(S)-Dolaphenine hydrochloride |
(S)-2-苯基-1-(噻唑-2-基)乙胺 |
135383-60-7 |
详细
|
Bohemine |
BOHEMINE |
189232-42-6 |
详细
|
AG-1478;AG1478;AG 1478;Tyrphostin AG-1478;NSC 693255 |
AG1478 |
153436-53-4 |
详细
|
α-Amylase |
α-淀粉酶 |
9000-90-2 |
详细
|
CCG-1423;CCG 1423;CCG1423 |
CCG1423 |
285986-88-1 |
详细
|
Infigratinib;BGJ-398;NVP-BGJ398 |
FGFR抑制剂(NVP-BGJ398) |
872511-34-7 |
详细
|
GW627368;GW 627368X |
GW627368X |
439288-66-1 |
详细
|
AM095 |
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐 |
1345614-59-6 |
详细
|
J-147;J147 |
J-147 |
1146963-51-0 |
详细
|
Oclacitinib;PF-03394197 |
奥拉替尼 |
1208319-26-9 |
详细
|
PF-06447475;PF06447475;PF 06447475 |
PF-06447475 |
1527473-33-1 |
详细
|
SKLB4771;FLT3-?IN-?1;FLT3-IN-1 |
FLT3-IN-1 |
1370256-78-2 |
详细
|
Apilimod;STA 5326 |
阿吡莫德 |
541550-19-0 |
详细
|
3-Hydroxyisobutyric acid;(S)-3-Hydroxyisobutyric acid |
2-甲基-3-羟基丙酸 |
2068-83-9 |
详细
|
Ponalrestat |
波来瑞斯 |
72702-95-5 |
详细
|
ASP3026;ASP 3026 |
ASP3026 |
1097917-15-1 |
详细
|
(R)-(-)-JQ1 Enantiomer |
(R)-(-)2-(4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-F][1,2,4]三唑并[4,3-A][1,4]二氮杂环庚烷-6-基)乙酸叔丁酯 |
1268524-71-5 |
详细
|
Taselisib;RG-7604;GDC-0032 |
GDC 0032 |
1282512-48-4 |
详细
|
AVN-944;VX-944;AVN944 |
化合物AVN944 |
297730-17-7 |
详细
|
CTX-0294885;CTx0294885 |
CTX0294885 |
1439934-41-4 |
详细
|
PFI-2;PFI2;PFI 2;(R)-PFI-2 |
PFI-2 |
1627676-59-8 |
详细
|
Dubermatinib;TP0903 |
TP-0903 |
1341200-45-0 |
详细
|
Ciproxifan maleate;FUB 359 maleate;FUB 359 |
环丙基[4-[3-(1H-咪唑-4-基)丙氧基]苯基]甲酮马来酸盐 |
184025-19-2 |
详细
|
JANEX-1;WHI-P131;Jak3 inhibitor I |
4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉 |
202475-60-3 |
详细
|
PD153035;ZM 252868;NSC 669364;AG1517;SU-5271 |
4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 |
153436-54-5 |
详细
|
ADX-47273;ADX 47273;BA 94673139 |
(S)-(4-氟苯基)-{3-[3-(4-氟苯基)-[1,2,4]二唑-5-基]哌啶-1-基}甲酮 |
851881-60-2 |
详细
|
Mertansine;DM1;Maytansinoid DM1 |
美登素 |
139504-50-0 |
详细
|
GS967;GS458967 |
GS967 |
1262618-39-2 |
详细
|
D-phenylalanine analogue;(R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid |
D-1,2,3,4-四氢异喹啉-3-羧酸 |
103733-65-9 |
详细
|
NG 52;NG52;NG-52;Compound 52 |
2-[[6-[(3-氯苯基)氨基]-9-异丙基-9H-嘌呤-2-基]氨基]乙醇 |
212779-48-1 |
详细
|
MLN9708;Ixazomib Citrate |
艾沙佐米柠檬酸盐 |
1201902-80-8 |
详细
|
LHW090-A7 |
(ALPHAS)-3'-氯-ALPHA-[[(1S)-2-乙氧基-1-甲基-2-氧代乙基]氨基][1,1'-联苯]-4-丙酸 |
1308256-94-1 |
详细
|
Defactinib;PF-04554878;VS-6063 |
地法替尼 |
1073154-85-4 |
详细
|
Mutant IDH1-IN-1;IDH1-IN-1 |
MUTANT IDH1-IN-1 |
1355326-21-4 |
详细
|
6-OAU;GTPL5846 |
GTPL5846 |
83797-69-7 |
详细
|
Dorsomorphin;BML-275;Compound C |
6-[4-[2-(1-哌啶基)乙氧基]苯基]-3-(4-吡啶基)吡唑并[1,5-A]嘧啶 |
866405-64-3 |
详细
|
SB-3CT |
SB-3CT |
292605-14-2 |
详细
|
Omecamtiv mecarbil;CK-1827452 |
4-[[2-氟-3-[N'-(6-甲基吡啶-3-基)脲基]苯基]甲基]哌嗪-1-羧酸甲酯 |
873697-71-3 |
详细
|
Capmatinib;INCB28060;NVP-INC280;INC-280 |
卡马替尼 |
1029712-80-8 |
详细
|
U-104;MST-104;NSC-213841;U104;U 104 |
U-104 |
178606-66-1 |
详细
|
KY02111 |
KY 02111 |
1118807-13-8 |
详细
|
NSC-41589;NSC41589;NSC 41589 |
化合物NSC-41589 |
6310-41-4 |
详细
|
VEGFR-2-IN-5;UNC0064-12;2,4-Pyrimidinediamine with linker;2, 4-Pyrimidinediamine with linker |
N2-[4-[(3-氨基丙基)氨基]苯基]-N4-(5-环丙基-1H-吡唑-3-基)-2,4-嘧啶二胺 |
1430089-64-7 |
详细
|
Altiratinib;DCC-2701 |
ALTIRATINIB |
1345847-93-9 |
详细
|
RQ-00203078;RQ00203078 |
4-(N-(3-氯-5-(三氟甲基)吡啶-2-基)-N-(4-(三氟甲氧基)苄基)氨基磺酰基)苯甲酸 |
1254205-52-1 |
详细
|
BML-277;C 3742;BML277;BML 277;Chk2 Inhibitor II |
2-(4-(4-CHLOROPHENOXY)PHENYL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE |
516480-79-8 |
详细
|
Fasoracetam |
法索西坦 |
110958-19-5 |
详细
|